Skip to main content

Table 1 Baseline patient characteristics

From: Effect of antiretroviral treatment on blood-brain barrier integrity in HIV-1 infection

  Longitudinal   Cross-sectional  
Characteristic NA HAD HAD untreated HAD treated
  (n = 82) (n = 10) (n = 47) (n = 20)
Gender: male, number (%) 49 (60) 9 (90) 44 (94) 18 (90)
Age (years) 38 (31–46) 41 (35–46) 40 (34–45) 45 (38–52)
CD4+ T-cell count (×  106 cells/L) 210 (70–330) 68 (60–137) 90 (17–175) 49 (38–52)
CD4+ nadir T-cell count (× 106 cells/L) 180 (60–250) 52 (16–80) 141 (18–160)c 65 (50–130)e
Plasma HIV RNA (log10 copies/mL) 4.79 (4.32–5.42) 5.49 (5.32–5.78) 4.87 (1.72–5.50) <  1.70
CSF HIV RNA (log10 copies/mL) 3.78 (3.23–4.38) 5.23 (5.09–5.41) 4.16 (2.78–4.98) <  1.70
Albumin ratio 4.26 (3.57–6.00) 10.6 (7.50–17.24) 9.90 (5.72–13.23) 6.57 (4.87–7.36)
CSF neopterin (nmol/L) 18.1 (11.5–24.0) 50.4 (43.1–85.8)a 50.0 (27.2–95.5) 13.5 (9.6–17.9)
CSF NfL (ng/L) 422 (318–713) 14,115 (9824–23,543)b 9731 (7603–21,555)d f
Follow-up, days 758 (230–1752) 241 (50–994) N/A N/A
  1. If not stated otherwise, values are presented as median (IQR). IQR interquartile range, CSF cerebrospinal fluid, NA neuroasymptomatic, HAD: HIV-associated dementia. Missing values: a2/10, b4/10, c40/47 d43/47, e15/20, fno values. CSF NfL as age-adjusted values